Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MCBNASDAQ:REVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMCBMetropolitan Bank$67.02+3.2%$63.33$38.56▼$69.56$692.37M1.0892,272 shs51,892 shsREVBRevelation Biosciences$0.77+3.8%$2.15$0.74▼$60.80$720K-0.09366,235 shs304,871 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMCBMetropolitan Bank0.00%+1.53%+2.06%+14.81%+67.11%REVBRevelation Biosciences0.00%-6.05%-69.30%-74.97%-97.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMCBMetropolitan Bank2.9904 of 5 stars2.51.00.00.02.62.53.1REVBRevelation Biosciences0.2343 of 5 stars0.02.00.00.00.60.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMCBMetropolitan Bank 3.00Buy$77.0014.89% UpsideREVBRevelation Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest REVB, MCB, ACRL, and W7L Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025MCBMetropolitan BankHovde GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform$75.00 ➝ $79.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMCBMetropolitan Bank$280.79M2.54$5.90 per share11.35$65.18 per share1.03REVBRevelation BiosciencesN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMCBMetropolitan Bank$66.69M$5.9111.347.79N/A13.49%10.53%1.02%7/17/2025 (Estimated)REVBRevelation Biosciences-$15.04M-$102.61N/AN/AN/AN/A-299.46%-115.36%8/8/2025 (Estimated)Latest REVB, MCB, ACRL, and W7L EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/17/2025Q2 2025MCBMetropolitan Bank$1.62N/AN/AN/A$72.50 millionN/A5/8/2025Q1 2025REVBRevelation Biosciences-$6.88-$2.11+$4.77-$2.11N/AN/A4/21/2025Q1 2025MCBMetropolitan Bank$1.61$1.45-$0.16$1.45$67.62 million$70.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMCBMetropolitan BankN/AN/AN/AN/AN/AREVBRevelation BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMCBMetropolitan Bank0.240.980.98REVBRevelation BiosciencesN/A3.603.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMCBMetropolitan Bank79.83%REVBRevelation Biosciences12.80%Insider OwnershipCompanyInsider OwnershipMCBMetropolitan Bank6.09%REVBRevelation Biosciences2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMCBMetropolitan Bank24010.66 million10.01 millionNot OptionableREVBRevelation Biosciences10964,000942,000Not OptionableACRL, REVB, MCB, and W7L HeadlinesRecent News About These CompaniesRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 31, 2025 | finance.yahoo.comRevelation Biosciences sets terms for $4 million public offeringMay 30, 2025 | investing.comRevelation Biosciences, Inc. (REVB) Raises $4M in Public OfferingMay 30, 2025 | insidermonkey.comRevelation Biosciences, Inc. Announces Closing of $4 Million Public OfferingMay 29, 2025 | businesswire.comRevelation Biosciences, Inc. Announces Pricing of $4 Million Public OfferingMay 29, 2025 | finance.yahoo.comRevelation Biosciences board member steps down amid new focusMay 25, 2025 | uk.investing.comRevelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of DirectorsMay 23, 2025 | businesswire.comREVB On Track and Exploring New MarketsMay 9, 2025 | msn.comRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, ...May 8, 2025 | gurufocus.comRevelation Biosciences to Develop Gemini for Infection in Severe Burn PatientsApril 29, 2025 | businesswire.comWhy Revelation Biosciences Inc. (REVB) Went Down On Thursday?April 10, 2025 | msn.comGemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear CellsMarch 17, 2025 | businesswire.comRevelation Biosciences to Host Fireside Chat at 37th Annual Roth ConferenceMarch 13, 2025 | businesswire.comRevelation Biosciences reports Q4 EPS ($4.98) vs ($133.64) last yearMarch 8, 2025 | markets.businessinsider.comRevelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD PatientsFebruary 26, 2025 | businesswire.comRevelation Biosciences, Inc. Receives Continued NASDAQ Listing ApprovalFebruary 24, 2025 | businesswire.comREVB Start 1B Trial and Announces SplitJanuary 29, 2025 | msn.comRevelation Biosciences Inc trading halted, news pendingJanuary 27, 2025 | markets.businessinsider.comRevelation Biosciences announces 1-for-16 reverse stock splitJanuary 24, 2025 | markets.businessinsider.comRevelation Biosciences stock hits 52-week low at $0.28January 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACRL, REVB, MCB, and W7L Company DescriptionsMetropolitan Bank NYSE:MCB$67.02 +2.07 (+3.19%) Closing price 03:59 PM EasternExtended Trading$67.04 +0.03 (+0.04%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Metropolitan Bank Holding Corp. operates as the bank holding company for Metropolitan Commercial Bank that provides a range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The company offers checking, savings, term deposit, money market, demand deposit, and other interest-bearing transaction accounts. It also provides lending products, including commercial real estate, multi-family, construction, and one-to four-family real estate loans; commercial and industrial loans; consumer loans; acquisition and renovation loans; loans to refinance or return borrower equity; loans on owner-occupied properties; working capital lines of credit; trade finance and letters of credit; and term loans. In addition, the company offers cash management services, as well as online and mobile banking, ACH, remote deposit capture, and debit cards. The company was formerly known as Metbank Holding Corp. and changed its name to Metropolitan Bank Holding Corp. in January 2007. Metropolitan Bank Holding Corp. was incorporated in 1997 and is headquartered in New York, New York.Revelation Biosciences NASDAQ:REVB$0.77 +0.03 (+3.75%) Closing price 04:00 PM EasternExtended Trading$0.77 -0.01 (-0.78%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
